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The eﬀects of indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019, or FFC14A), the second ruthenium
compound that entered clinical trials, in an in vitro model of tumour invasion and metastasis show that the antitumour eﬀects
of this compound might include also the modulation of cell behaviour although its cytotoxicity appears to be predominant over
these eﬀects. The comparison with its imidazole analogue KP418 shows however its superiority, being able to control in vitro cell
growth and in some instances also in vivo tumour development. These results suggest that the activity of KP1019 is predominantly
due to direct cytotoxic eﬀects for tumour cells, evident also in vivo on primary tumour growth and that the eﬀects on modulation
of the biological behaviour of the cancer cell can be present but might have only a partial role.
Copyright © 2009 A. Bergamo et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
The research on anticancer innovative drugs based on the
ruthenium metal received a strong impulse from the exten-
sive knowledge of the coordination and redox properties of
metal ions. The knowledge of the role of the “activation
by reduction” hypothesis [1, 2], suggesting the reduced
Ruthenium(II) species as the ﬁnal reactive drug, prompted
the development of Ruthenium(III) compounds with the
aim of getting prodrugs activated selectively in the hypoxic
environment of solid tumours. The study of complexes
with a redox potential accessible to the biological redox
environment has led to the identiﬁcation of the antitumour
propertiesofseveralcomplexesamongwhichtheseriesofso-
called “ruthenium bis-heterocycle” complexes characterised
by heterocycle ligands placed in the axial position have been
tested in vitro and in vivo. One of them, namely, indazolium
trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019
or FFC14A) is receiving attention for its activity against
varioustumortypesinvivoasindicatedbystablediseaseseen
in heavily pretreated cancer patients in a phase I trial [3].
The aim of this study is to evaluate the eﬀects of
KP1019, in comparison to its bis-imidazole analogue KP418
(Figure 1), in an in vitro model of tumour invasion and
metastasis. Although isostructural with KP1019, KP418
showed a slower reduction rate [4], but higher toxicity in
therapeutically active doses in vivo in a model of chemically
induced autochthonous colorectal cancer [5]a n dv e r yl o w
cytotoxicity in human cancer cell lines [6]. Eﬀects of KP1019
(but not KP418) on adhesion properties of cancer cells were
ﬁrst suggested by the simple observation that human SW480
colon carcinoma cells resist harvesting by trypsinisation
upon treatment with KP1019 in concentrations in the
10
−4 M range for as short as 30 minutes [6]. Microscopic
examination revealed structures tentatively considered as
stressﬁbres(B.Marian,personalcommunication).Although
not examined in detail, these observations were reminis-
cent of the strong actin-dependent adhesion of tumour
cells induced by short-term exposure to the investigational
antimetastatic ruthenium-based drug NAMI-A [7], raising
the question whether KP1019 is capable of aﬀecting cellular
properties related to the processes of tumour invasion and
metastasis.
The metastatic progression is mimicked in vitro by
opportune experiments to study cell detachment from
the primary tumour, extracellular matrix degradation, cell2 Metal-Based Drugs
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Figure 1: Chemical structures of NAMI-A, KP1019, and KP418.
ability to migrate in response to chemical or contact stimuli,
invasion, and readherence to a substrate, with the use of
cell lines of the mammary gland with diﬀerent degree
of aggressiveness: MDA-MB-231, a highly invasive breast
cancer cell line, MCF-7, a tumorigenic but not invasive
cell line, and HBL-100, a non-tumorigenic cell line of
the mammary epithelium. The in vitro study is compared
with the antitumour and antimetastatic eﬀects of the same
compounds in vivo in the mouse model of MCa mammary
carcinoma.
2.MaterialsandMethods
2.1. Drugs and Reagents. KP418 and KP1019 were prepared
according to the published procedures [8, 9]. All reagents
were purchased from Sigma-Aldrich (St. Louis, Mo, USA)
unless otherwise indicated.
2.2. Tumor Cell Lines for In Vitro Tests. The MDA-MB-231
human highly invasive breast cancer cell line was kindly
supplied by Dr. P. Spessotto (Cro, Aviano, Italy), and main-
tained in Dulbecco’s modiﬁed Eagle’s medium (EuroClone,
Devon, UK) supplemented with 10% FBS (Gibco, Invitro-
gen, Paisley, Scotland, UK), 2mM L-glutamine (EuroClone,
Devon, UK), 1% non-essential aminoacids, and 100IU/mL
penicillin and 100µg/mL streptomycin (EuroClone, Devon,
UK).
The MCF-7 human breast cancer cell line was obtained
from the American Type Culture Collection (Manassas, VA;
catalogue number HTB-22) and maintained in Dulbecco’s
modiﬁed Eagle’s medium/F12 medium 1 : 1 v/v (Euro-
Clone, Devon, UK) supplemented with 10% FBS, 2mM L-
glutamine, and 100IU/mL penicillin as well as 100µg/mL
streptomycin.
The HBL-100 human non-tumorigenic epithelial cell
line was kindly supplied by Dr. G. Decorti (Department
of Biomedical Sciences, University of Trieste, Italy), and
maintained in McCoy’s 5A medium supplemented with
10% FBS, 2mM L-glutamine, and 100IU/mL penicillin and
100µg/mL streptomycin.
A l lc e l ll i n e sw e r ek e p ti naC O 2 incubator with 5% CO2
and 100% relative humidity at 37
◦C. Cells from a conﬂuent
monolayer were removed from ﬂasks by a trypsin-EDTA
solution. Cell viability was determined by the trypan blue
dye exclusion test [10]. For experimental purposes cells were
sown in multiwell culture clusters.
2.3. Resistance to Detachment Assay. The cells ability to resist
detachment after treatment with KP418 and KP1019 was
measured by the following. 96 well plastic plates (Corning
Costar, Milano, Italy) were coated with the following sub-
strates: 10µg/mL poly-L-lysine, 20µg/mL ﬁbronectin from
human plasma, and 20µg/mL collagen IV from human
placenta, and left in a humidiﬁed cell-culture chamber at
37
◦C for 4 hours. Before cell seeding, plates were washed
with CMF-DPBS (Calcium and Magnesium Free Dulbecco’s
Phosphate Buﬀered Saline), then 6 ·103 cells in 0.2mL
complete medium were sown in each well. After 2 days at
37
◦C, complete medium was replaced with serum-starved
medium, containing 0.1% w/v BSA. After 24 hours the
medium was removed and the plates washed with CMF-
DPBS,beforethetreatmentwithKP418andKP101910
−4M,
dissolved in DPBS (Dulbecco’s Phosphate Buﬀered Saline),
was added to the wells and incubated for 1 hour. At the
end of the treatment the KP418- and KP1019- containing
solutions were removed, the plates were washed twice with
CMF-DPBS, and trypsin solution, 0.008% w/v, was added
to each well. Plates were kept in agitation for 30 minutes at
room temperature then trypsin solution was removed and
wells washed with CMF-DPBS. Cells that still adherent to
the plates were detected by the sulforhodamine B (SRB)
test. Resistance to detachment is expressed as arbitrary units,
calculated by dividing the mean absorbance of treated cells
by the mean absorbance of control cells.Metal-Based Drugs 3
2.4. Re-adhesion Assay. The eﬀect of the ability of the cells
to readhere after KP418 and KP1019 treatment was studied
in cells maintained for 24 hours in serum-starved medium,
and then treated for 1 hour with KP418 and KP1019
10
−4 M in DPBS. At the end of the treatment cells were
removed from ﬂasks by a trypsin-EDTA solution, collected
by centrifugation, resuspended in serum-starved medium
supplemented with 0.1% w/v BSA and kept for 30 minutes at
room temperature to allow surface receptor reconstitution.
The cells were then seeded at a density of 1 · 104 cells in
0.1mL/well on 96 well plastic plates previously coated as
described above with poly-L-lysine, ﬁbronectin, collagen IV
or20µg/mLMatrigel(BD,Biosciences,SanJos` e,Calif,USA).
Cells were left to adhere for 30 and 60 minutes at 37
◦C
with 5% CO2 and 100% relative humidity, then the medium
containing the non-adherent cells was removed and wells
were gently washed with CMF-DPBS. Cells that in 30 or 60
minutes have adhered to the substrates were detected by the
sulforhodamine B (SRB) test.
2.5. Sulforhodamine B Assay. Adherent cells were detected
with the SRB test described by Skehan et al., [11]. Brieﬂy,
adherent cells were ﬁxed with 10% v/v cold trichloroacetic
acid (TCA) at 4◦C for 1 hour. After ﬁxation TCA was
discarded and wells washed ﬁve times with distilled water
and air-dried. SRB solution (0.4% w/v, in 1% acetic acid)
was added to the wells and plates were kept for 30 minutes at
room temperature. Unbound SRB was removed by washing
three times with 1% acetic acid. Plates were air dried, then
bound stain was dissolved with un-buﬀered 10mM Tris
base (tris-hydroxymethyl-aminomethane) at pH 10.5 and
the optical density was read at 570nm with an automatic
computerised spectrophotometer (SpectraCount; Packard,
Meriden, Conn, USA).
2.6. Migration Assays. Migratory ability resulting from a
haptotactic or a chemotactic stimulus was measured in
Transwell cell culture chambers (Costar, Milano, Italy).
In the haptotaxis assay the lower surface of the a
polyvinylpyrrolidone-free polycarbonate ﬁlter (8-µmp o r e
size) was coated with 10µg/mL ﬁbronectin and left in
a humidiﬁed cell culture chamber at 37
◦Cf o r2h o u r s ,
then washed with CMF-DPBS before cell seeding. In the
chemotaxis assay inserts were used without coating. Cells
were treated for 1 hour with KP418 and KP1019 10
−4 M
and with KP1019# (# is equal to 10
−6 M for MDA-MB-231
and MCF-7 and to 10
−5 M for HBL-100) in DPBS. After
treatment, cells were removed with a trypsin-EDTA solution,
collected by centrifugation, resuspended in serum-starved
medium supplemented with 0.1% w/v BSA, and 1 · 105 cells
in 0.2mL were sown in the upper compartment of each
chamber. The lower compartment was ﬁlled with serum-
starved medium supplemented with 0.1% w/v BSA, and with
complete medium for the haptotaxis and the chemotaxis
assay, respectively.
Cells were left to migrate for 24 hours, then the cells on
the upper surface of the ﬁlters were removed with a cotton
swab and migrating cells, present in the lower surface, were
detected by the crystal violet assay.
2.7. Invasion Assay. Invasive ability was measured in a Tran-
swell cell culture chamber according to the method of Albini
et al. [12]. Brieﬂy, the upper surface of the polycarbonate
ﬁlter (8µm pore size) of Transwell cell culture chambers
was coated with 50µL of a 600µg/mL Matrigel solution and
air dried overnight at room temperature. The ﬁlters were
reconstituted with DMEM medium for 90 minutes under
gently shaking immediately before use. Cells were treated as
describedforthemigrationassaysand0.5·105 cellsin0.2mL
were sown in each chamber. Cells were left invade for 96
hours, then the cells on the upper surface of the ﬁlters were
removedwithacottonswabandinvadingcells,presentinthe
lower surface, were detected by the crystal violet assay.
2.8. Crystal Violet Assay. The crystal violet assay was per-
formed according to the method described by Kueng et al.,
[13]. Brieﬂy, the cells present on the lower surface of the
ﬁlter were ﬁxed with a 1.1% w/v glutaraldehyde solution for
15 minutes. After ﬁxation the wells were washed three times
with distilled water and air dried. Cells were stained for 20
m i n u t e sw i t h0 . 1 %w / vc r y s t a lv i o l e tp r e p a r e di n2 0 0 m M
boric acid, pH 9.0, then washed three times with distilled
water and air-dried prior to dissolve the dye with 10% acetic
acid solution. The optical density was read at 590nm with an
automatic computerised spectrophotometer (SpectraCount;
Packard, Meriden, Conn, USA).
2.9. Cell Viability. To evaluate if treatment with KP418
and KP1019, in the experimental conditions adopted, can
aﬀect cell viability, cells were treated as described above
for migration tests, except they were seeded on 96 well
plates. Brieﬂy, cells treated in culture ﬂasks for 1 hour with
10
−4 M KP418 or with 10
−6,1 0
−5,a n d1 0
−4 M KP1019 were
detached and sown on 96-well plates and, after additional
24 hours incubation in culture medium, cell viability was
detected by the MTT viability test [14]. Brieﬂy, a solution of
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] dissolved in CMF-DPBS (5mg/mL) was added to
each well (10µL per 100µL of medium) and the plates were
incubated at 37
◦Cw i t h5 %C O 2 and 100% relative humidity
for 4 hours. After this time, the medium was discarded
and 200µL of DMSO were added to each well to dissolve
the formazan crystals. The optical density was measured at
570nm with an automatic computerised spectrophotometer
(SpectraCount; Packard, Meriden, Conn, USA).
2.10. Zymography. To visualise the direct eﬀect of KP418
and KP1019 on the activity and/or production of MMP-
2 and MMP-9 enzymes, sodium dodecyl sulphate (SDS)
polyacrylamide gel electrophoresis (PAGE) zymography was
carried out with conditioned medium of MDA-MB-231
and HBL-100 cells. Cells at 70% conﬂuence were incubated
for 24 hours in serum-starved medium containing 0.1%
BSA, before being treated with KP418 and KP1019 10
−4 M
for 1 hour. At the end of the treatment, the KP418 and
KP1019 solutions were discarded and complete serum-free
medium containing 0.1% w/v BSA was added for a further
24 hours, when culture media were collected, centrifuged
to remove cellular debris, then concentrated approximately4 Metal-Based Drugs
15 times using Amicon Ultra-15 30,000 nominal molecular
weightlimitcentrifugalﬁlterdevices(MilliporeCorporation,
Bedford, Mass, USA). The conditioned media obtained were
stored at −80
◦C until use. Equal amounts of proteins, as
determined by the Bradford method [15], for each sample
were eluted with Laemmli non-reducing sample buﬀer
and analysed by SDS-PAGE on a 7% polyacrylamide gel
containing0.1%w/vgelatine.Attheendofelectrophoresisin
a dual-laboratory system (Protean II, Bio-Rad Laboratories,
Hercules, CA, USA), the gels were washed two times for 30
minutes at 4◦C in 2.5% Triton X-100 to remove SDS. After
additional washing in water (three times for 5 minutes), the
gels were incubated at 37
◦C overnight in collagenase buﬀer
(200mM NaCl, 50mM tris(hydroxymethyl)aminomethane,
5mMCaCl 2,a d j u s t e dt op H7 . 4 )t or e a c t i v a t ee n z y m ea c t i v -
ity. The gels were then stained with 0.5% Coomassie brilliant
blue. The gelatinolytic regions were observed as white bands
against a blue background. Quantitative evaluation of the
band intensity, on the basis of grey levels, was performed
using Image Master 2D version 4.01 and Magic Scan 32
version 4.3 software.
2.11. In Vivo Tests. The in vivo experiments were carried
out with the murine mammary carcinoma (MCa), originally
obtained from the Department of Biology, Rudjer Boskovich
Institute (Zagreb, Croatia), grown in CBA female mice,
obtained from a local breeding colony grown according to
the standard procedures for inbred strains [16]. The tumour
line was locally maintained by serial biweekly passages of
106 viable tumour cells, of a cell suspension prepared from
mincing(withscissors)theprimarytumourmassesobtained
fromdonors similarlyimplanted 2weeksbefore.Theminced
tissue was ﬁltered through a double layer of sterile gauze,
centrifuged at 250xg for 10 minutes, and resuspended in an
equal volume of CMF-DPBS; viable cells were counted by
the trypan blue exclusion test. 106 viable tumour cells were
injected I.M. into the left hind calf of experimental groups.
KP1019 was administrated as 10% DMSO solution in sterile
saline (0.9% NaCl) and given to mice by I.P. administrations
at two dose levels of 40mg/kg/day from day 6 to day 11 after
tumour implant, and 80mg/kg/day on days 7, 9, and 11 after
tumour implant.
Primary tumour growth was determined by calliper
measurements, by measuring two orthogonal axes, and the
tumour volume was calculated with the formula: (Π/6)
xa2 xb,w h e r ea is the shorter axis and b the longer axis,
assuming tumour density equal to 1g/mL. The evaluation of
the number and weight of lung metastases was performed
by examining the surface of the lungs immediately after
sacriﬁcing the animals by cervical dislocation. Lungs were
dissected into ﬁve lobes, washed with CMF-DPBS, and
examined under a low power microscope equipped with a
calibrated grid. The weight of each metastasis was calculated
by applying the same formula used for primary tumours and
the sum of each individual weight gave the total weight of
metastatic tumour per animal.
2.12. Animal Studies. Animal studies were carried out
according to guidelines enforced in Italy (DDL 116 of
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Figure 2: Eﬀect of KP418 and KP1019 on resistance to detachment.
MDA-MB-231, MCF-7, and HBL-100 cells seeded on 96-well
plastic plates previously coated with poly-L-lysine, ﬁbronectin and
collagen IV, exposed for 1 hour to KP418 and KP1019 10
−4 Ma n d
then to a diluted trypsin solution for 30 minutes, before detecting
cells still attached to the growth substrate by the SRB test. Arbitrary
units are calculated from the mean ± S.D. of two experiments, each
performed in quadruplicate. ∗, P<. 05; ∗∗, P<. 01; ∗∗∗, P<. 001
versus controls, ANOVA, and Tukey-Kramer post test.
21/2/1992 and subsequent addenda) and in compliance
with the Guide for the Care and Use of Laboratory Ani-
mals(National Academy Press, Washington, D.C. CSSG) .
2.13. Statistical Analysis. Results were subjected to comput-
er-assisted statistical analysis using the One-Way Analysis of
Variance ANOVA, and the Tukey-Kramer post-test. Diﬀer-
ences of P<. 05 were considered to be signiﬁcantly diﬀerent
from the controls.
3. Results
3.1. Resistance to Detachment. The resistance to detachment
is an index of the propensity of tumour cells to detach from
the primary site of growth with the aim to disseminate.
This ability was studied by seeding cells on components of
the extra cellular matrix (ECM) such as ﬁbronectin (F) and
collagen IV (C) and, for comparison, on poly-L-lysine (P)
a substrate on which cells simply adhere by electrostatic
interactions (Figure 2). KP1019 increased the resistance to
detachment of the MDA-MB-231 cells much better than that
ofthelowinvasiveMCF-7cellsorthenon-tumorigenicHBL-
100 cells, independently of the substrate on which cells are
grown. KP418 showed a similar behaviour and globally its
eﬀects were lower than those of KP1019.
3.2. Re-adhesion after Treatment. The propensity to readhere
to ﬁbronectin (F), collagen IV (C), and Matrigel (M), in
comparison to poly-L-lysine (P), of MDA-MB-231, MCF-
7, and HBL-100 cells, following 1 hour challenge withMetal-Based Drugs 5
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Figure 3: Eﬀect on ability of cells to readhere after KP418 and
KP1019 treatment. MDA-MB-231, MCF-7, and HBL-100 cells were
treated for 1 hour with KP418 and KP1019 10
−4 M, then the cells
were removed from the ﬂasks, collected, resuspended and seeded
on 96-well plastic plates previously coated with poly-L-lysine,
ﬁbronectin, collagen IV and Matrigel. After 30 and 60 minutes of
incubation cells that adhered to the substrates were detected by the
SRBtest.Dataarethepercentofvariationversuscontrolscalculated
from the mean ± S.D. of two experiments, each performed in
triplicate. ∗, P<. 05 versus controls, ANOVA, and Tukey-Kramer
post test.
10
−4 M KP1019 and KP418 was studied exposing cells to the
compoundswhiletheywereadherenttothegrowthsubstrate
(Figure 3). The two metal compounds show no signiﬁcant
modiﬁcations of the cell ability to readhere after treatment
with the exception of KP1019 that signiﬁcantly reduces the
attachment of MCF-7 to ﬁbronectin.
3.3. Eﬀects on Migration and Invasion. The eﬀects of KP1019
and KP418 on cell migration were determined with properly
adapted Transwell chambers, where the cells were subjected
to a chemical (chemotaxis) or a contact (haptotaxis) stim-
ulus to promote cell movement (Figure 4). Treatment with
10
−4 M KP1019 for 1 hour caused a statistically signiﬁcant
and pronounced reduction of cell migration, independently
of the stimulus being applied and of the cell line being used.
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Figure4:EﬀectofKP418andKP1019onmigrationofcellsthrough
polycarbonate ﬁlters. MDA-MB-231, MCF-7, and HBL-100 cells
were treated for 1 hour with KP418, KP1019 10
−4 M, and KP1019#
(# is equal to 10
−6 M for MDA-MB-231 and MCF-7 and to 10
−5 M
forHBL-100),thenthecellswereremovedfromtheﬂasks,collected,
resuspended, and seeded on the inserts of Transwell cell culture
chambers.Datarepresentcellsthatafter24hourshavemigratedand
are present on the lower surface of the ﬁlter. Data are the percent of
variation versus controls calculated from the mean ± S.D. of two
experiments each performed in triplicate, ∗: P<. 05; ∗∗: P<. 01;
∗∗∗: P<. 001 versus controls, ANOVA, and Tukey-Kramer post
test.
10
−4 M KP418 is almost completely devoid of eﬀects in these
tests with the exception of a mild reduction of cell response
to haptotaxis of MCF-7 cells.
The invasion ability of the same cells, studied on
Transwell chambers coated with a 3D matrix, (Figure 5)w a s
similarly aﬀected by 10
−4 M KP1019 while 10
−4 M KP418
again reduced the invasion of only MCF-7 cells.
3.4.EﬀectonCellV iability . ThestudyoftheeﬀectsofKP1019
and KP418 on cell viability was done in the same condition
at which the two ruthenium complexes were tested on cell
migration,thatis,1hourat10
−4 M,orlowerdosesinthecase
it is found to signiﬁcantly reduce cell growth as compared6 Metal-Based Drugs
Table 1: Eﬀect of KP418 and KP1019 on cell viability.
MDA-MB-231 MCF-7 HBL-100
Controls 2.284 ± 0.066 2.631 ± 0.055 2.308 ± 0.424
KP418 (10
−4 M ) 1.832 = 0.046∗ 2.763 ± 0.040 2.269 ± 0.159
(79.9%) (105%) (97.0%)
MDA-MB-231 MCF-7 HBL-100
Controls 1.482 ± 0.016 1.178 ± 0.073 0.999 ± 0.055
KP1019 (10
−6 M) 1.435 ± 0.040 1.184 ± 0.051 1.076 ± 0.055
(96.8%) (101%) (107%)
KP1019 (10
−5 M) 1.361 ± 0.050∗∗∗ 1.04 ± 0.039∗ 0.901 ± 0.081
(91.8%) (88.3%) (90.2%)
KP1019 (10
−4 M) 0.847 ± 0.022∗∗∗ 0.862 ± 0.098∗∗∗ 0.328 ± 0.056∗∗∗
(57.2%) (73.2%) (32.9%)
MDA-MB-231, MCF-7, and HBL-100 cells were treated for 1 hour with KP418 10−4 M and KP1019 10−6 ÷ 10−4 M, then the cells were removed from the
ﬂasks, collected, resuspended in culture medium and seeded on 96 well plates. After 24 hours cell viability was determined by the MTT assay. Data are the
mean optical density ±S.D. of two experiments each performed in quadruplicate. Data in parentheses represent the percentage of each treated group versus
the relevant controls (T/C%), ∗: P<. 05, ∗∗∗: P<. 001 versus controls, ANOVA, and Tukey-Kramer post test.
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Figure 5: Eﬀect of KP418 and KP1019 on invasion of cells through
Matrigel. MDA-MB-231, MCF-7, and HBL-100 cells were treated
for 1 hour with KP418, KP1019 10
−4 M, and KP1019# (# is equal to
10
−6 Mf o rM D A - M B - 2 3 1a n dM C F - 7a n dt o1 0
−5 M for HBL-100),
then the cells were removed from the ﬂasks, collected, resuspended
and seeded on inserts. Data represent cells that after 96 hours have
invaded and are present on the lower surface of the ﬁlter. Data are
the percent of variation versus controls calculated from the mean
±S.D. of two experiments, each performed in triplicate, ∗: P< . 05:
∗∗∗: P< . 001 versus controls, ANOVA, and Tukey-Kramer post
test.
to untreated controls, with analysis after additional 24 hours
in culture medium. Data reported in Table 1 show KP418 to
cause a very mild reduction of cell growth of the invasive
MDA-MB-231 cells with non appreciable eﬀects on the
less malignant MCF-7 cells or the non-tumorigenic HBL-
100 cells. KP1019, in the same experimental conditions,
was much more cytotoxic, maintaining a certain degree of
cytotoxicity also at the lower dosage of 10
−5 M.
3.5. Eﬀe c to nM M P sP r o d u c t i o na n dA c t i v i t y .The eﬀects of
the two metal compounds on the matrix metallo proteinases
(MMP-2 and MMP-9) production and/or activity were
studied with the gelatine zymography test. MDA-MB-231
cells produce the 92KDa MMP-9 in appreciable amounts
whereas HBL-100 cells prevalently produce the 72KDa
MMP-2. KP1019 reduced the production/activity of both
MMP-2 and MMP-9 by approximately 65–75% of controls,
whereas KP418 reduced MMP-9 activity by about 40% of
controls (Figure 6).
3.6. Eﬀe c to nL u n gM e t a s t a s e sI nV i v o .The eﬀects of
KP1019 treatment on primary tumour growth and lung
metastasis formation were studied in the model of MCa
mammary carcinoma, a murine transplantable tumour that
spontaneously metastasise to the lungs (Table 2). The daily
administration of 40mg/kg/day from day 6 to day 11, or
80mg/kg/day on days 7, 9, and 11 after tumour implantation
caused a comparable and statistically signiﬁcant reduction of
thegrowthoftheintramusculartumourmorepronouncedat
the end of the treatment schedule than a week later. None of
thetreatmentsreducedthedevelopmentoflungmetastatases
in this tumour model.
4. Discussion
KP418 is mostly known for its capacity to reduce the
growth of an autochthonous colorectal cancer induced
by carcinogens in the rat [5]. In spite of its similarities
with NAMI-A (they diﬀer only in a ligand, imidazole in
KP418 and dimethylsulfoxide in NAMI-A), KP418 shows a
completely diﬀerent pharmacological proﬁle. Even though
the biodistribution patterns of KP418 and NAMI-A are
virtually identical in the Lewis lung carcinoma model [17],
NAMI-Ahasnoeﬀectontheprimarytumorbutasigniﬁcant
eﬀect on the metastases, while KP418 has a mild cytotoxic
eﬀect on the primary tumour but no signiﬁcant eﬀect on
the growth of distant metastases. These diﬀerences might be
attributed to the solution chemistry characteristics of theseMetal-Based Drugs 7
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Figure 6: Eﬀect of KP418 and KP1019 on MMPs production and/or activity. MDA-MB-231, and HBL-100 cells were treated for 1 hour with
KP418 and KP1019 10
−4 M, then incubated for additional 24 hours in serum-starved complete medium containing 0.1% BSA. Supernatants
containing MMPs were collected and concentrated and equal protein amounts (100µg) subjected to SDS-PAGE. Gelatine digestion by
proteases is detected as white bands against a blue background (a, b). Band digestion is quantiﬁed by using Image Master 2D version 4.01
and Magic Scan 32 version 4.3 software (c).
Table 2: Eﬀect of KP1019 on lung metastases formation in mice with MCa mammary carcinoma.
(A) Primary tumour weight (mg) Lung metastases†
Day 13 Day 20 Number Weight (mg)
Controls 1627 ± 286 3068 ± 616 29.2 ± 8.10 18.6 ± 12.1
KP1019 40mg 1095 ± 592 2537 ± 563 31.9 ± 19.2 11.8 ± 11.8
(67%) (83%) (109%) (63%)
(B) Primary tumour weight (mg) Lung Metastases†
Day 13 Day 20 Number Weight (mg)
Controls 1004 ± 174 2415 ± 439 17.5 ± 10.0 5.70 ± 6.90
KP1019 80 mg 527 ± 136.662∗∗∗ 1764 ± 370∗∗∗ 19.9 ± 23.2# 3.43 ± 5.83#
(52%) (73%) (114%) (60%)
Groups of 9 (experiment A) or 11 (experiment B) CBA mice, inoculated I.M. with 106 MCa tumour cells on day 0 were treated I.P. with KP1019 at
40mg/kg/day from day 6 to day 11 (A) and 80mg/kg/day on days 7, 9, and 11 (B) after tumour implant. Data in parentheses are expressed as the percentage
of the treated versus controls (T/C%), † Lung metastases were determined on day 20 after tumour implant, ∗∗∗: P<. 001 versus controls, ANOVA, and
Tukey-Kramer post test, #: excluded the animals free of macroscopically detectable metastasis (2/11).
compounds, with NAMI-A being much more sensitive to
reduction than KP418 [18].
From this point of view, KP1019 might be expected to
combine the activities of both KP418 and NAMI-A, as it
shares the cytotoxic eﬀects on the primary tumour with the
formerandtheredoxsensitivitywiththelattercompound,as
a consequence of the replacement of the twotransimidazoles
with two indazole moieties [4]. In comparison with KP418,
KP1019 had already proved to be at least as eﬀective on
primarycolorectaltumoursintherat,butwiththeadvantage8 Metal-Based Drugs
of being nearly completely devoid of toxic side eﬀects at the
active doses used [5]. Moreover, the ability of KP1019 to
induce enhanced adhesion of tumour cells (see Section 1)
suggested a vague similarity with NAMI-A. In this study, we
chose to investigate whether a component resembling the
activityofNAMI-A,thatis,reductionoftumourmalignancy,
is involved in the antitumour eﬀects of KP1019 beside the
previously described apoptotic mechanisms [6, 19].
Overall, the results of this study indicate that activity of
KP1019 in murine mammary carcinoma in vivo is primarily
not due to interference with the processes of tumour cell
invasion and metastasis. Although inhibition of the primary
tumour was demonstrated and inhibition of the increase
of metastases weight suggested (without reaching statistical
signiﬁcance), the number of metastases was unaﬀected. We
therefore conclude that any activity of KP1019 on metastases
is due to direct cytotoxic eﬀects, just as those on the primary
tumor, rather than to the modulation of the biological
behaviour of the cancer cell.
On the other hand, KP1019, unlike its isostructural
analogueKP418,provedtobeeﬀectiveinamodelmimicking
cell invasion and metastasis in vitro. However, the data
presented suggest that the strong inhibition of tumour cell
invasion and the reduction of tumour cell migration upon
chemotactic and haptotactic stimuli depend on the use of
cytotoxic concentrations, but not on the malignancy of the
tumour cell line, as the eﬀects on the metastatic MDA-
MB-231 cells equal those on the non-tumorigenic HBL-
100 cells. Additionally, KP1019 clearly reduces the release
of metalloproteases of the extracellular matrix (MMP-2
and MMP-9), enzymes often associated with unfavourable
prognosis in many cancers including mammary tumours
[20, 21].
These eﬀects are indirectly dependent on the chemical
consequences of the indazole ligands that replace the imi-
dazoles of KP418, since KP418 is virtually devoid of eﬀects
in any of the tests performed. We have already noted that
the redox potentials of KP1019 and NAMI-A are similar
and biologically accessible, whereas KP418 is much less
sensitive to reduction. Based on the observation that NAMI-
A is active as an antimetastatic agent, while KP418 is not,
it was hypothesized that sensitivity to biological reduction
may play a role in antimetastatic agents. The data obtained
with KP1019 suggest that this hypothesis may be incorrect.
For NAMI-A, a drug for which the possibility to undergo
reduction by biological reductants was repeatedly shown
([22]andreferencescitedherein),thismeansthatitsselective
eﬀects on metastases might be due to other factors than to a
simple reduction.
Finally, these data show that the challenge of the in
vitro model simulating some of the most relevant steps
of metastasis formation, with a cytotoxic ruthenium com-
pound, such as KP1019, validates the claimed role of this
model, highlighted with the lead NAMI-A (Callerio Foun-
dation, conﬁdential data), to identify compounds endowed
of selective eﬀects on metastases in the virtual absence of
direct cell cytotoxicity, even when these eﬀects are mild and
less pronounced than those of NAMI-A, as reported with the
organometallic compound RAPTA-T [23].
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